Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Immune-Oncology Strategy Suffers Setback

This article was originally published in Scrip

Executive Summary

AstraZeneca Plc's strategy of pushing the development combination therapies to offset its relatively tardy start in immune-oncology has suffered a setback. It has suspended recruitment into two trials which are testing the effectiveness of a combination of AZD9291 and durvalumab (MEDI4736) in non-small cell lung cancer (NSCLC) following an increased incidence of lung disease. Durvalumab is in a number of trials with external collaborators which will be following this development closely. Meanwhile, Clovis Oncology Inc., which has a competitor product to AZD9291 – rociletinib – will also be a keen observer. Both products are due to be filed as monotherapies next year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel